4.5 Article

Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jaac.2020.11.023

Keywords

selective serotonin reuptake inhibitor (SSRI); antidepressant; clinical trial; anxiety disorders; MRI

Funding

  1. National Institute of Mental Health [K23 MH106037]
  2. Eunice Kennedy Shriver National Institute of Child Health and Human Development [R01 HD098757]
  3. National Institute of Environmental Health Sciences [R01 ES027224]
  4. National Natural Science Foundation of China [81820108018, 81621003, 8202780056]

Ask authors/readers for more resources

In adolescents with generalized anxiety disorder (GAD), escitalopram increased amygdala-prefrontal connectivity within the first 2 weeks of treatment, and the magnitude of this early change predicted subsequent clinical improvement.
Objective: Amygdala-ventrolateral prefrontal cortex (VLPFC) circuitry is disrupted in pediatric anxiety disorders, yet how selective serotonin re -uptake inhibitors (SSRIs) affect this circuitry is unknown. We examined the impact of the SSRI escitalopram on functional connectivity (FC) within this circuit, and whether early FC changes predicted treatment response in adolescents with generalized anxiety disorder (GAD). Method: Resting-state functional magnetic resonance (MR) images were acquired before and after 2 weeks of treatment in 41 adolescents with GAD (12-17 years of age) who received double-blind escitalopram or placebo for 8 weeks. Change in amygdala-based whole-brain FC and anxiety severity were analyzed. Results: Controlling for age, sex, and pretreatment anxiety, escitalopram increased amygdala-VLPFC connectivity compared to placebo (F = 17.79, p = .002 FWE-corrected). This early FC change predicted 76.7% of the variability in improvement trajectory in patients who received escitalopram (p < .001) but not placebo (p = .169); the predictive power of early amygdala-VLPFC FC change significantly differed between placebo and escitalopram (p = .013). Furthermore, this FC change predicted improvement better than baseline FC or clinical/demographic characteristics. Exploratory analyses of amygdala subfields' FC revealed connectivity of left basolateral amygdala (BLA)-VLPFC (F = 19.64, p < .001 FWE-corrected) and superficial amygdala-posterior cingulate cortex (F = 22.92, p = .001 FWE-corrected) were also increased by escitalopram, but only BLA-VLPFC FC predicted improvement in anxiety over 8 weeks of treatment. Conclusion: In adolescents with GAD, escitalopram increased amygdala-prefrontal connectivity within the first 2 weeks of treatment, and the magnitude of this change predicted subsequent clinical improvement. Early normalization of amygdala-VLPFC circuitry might represent a useful tool for identifying future treatment responders as well as a promising biomarker for drug development. Clinical trial registration information: Neurofunctional Predictors of Escitalopram Treatment Response in Adolescents With Anxiety; https:// www.clinicaltrials.gov/; NCT02818751.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available